Anzeige
Mehr »
Samstag, 21.03.2026 - Börsentäglich über 12.000 News
Drohnen statt Panzer: Beginnt hier der nächste Milliarden-Superzyklus?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41C99 | ISIN: US08862L2025 | Ticker-Symbol: 48L0
NASDAQ
20.03.26 | 20:59
0,772 US-Dollar
-0,99 % -0,008
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
BEYOND AIR INC Chart 1 Jahr
5-Tage-Chart
BEYOND AIR INC 5-Tage-Chart

Aktuelle News zur BEYOND AIR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiBeyond Air: Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial1
10.03.Beyond Air halts sale of NeuroNOS subsidiary to XTL BioPharmaceuticals1
10.03.Beyond Air Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.597GARDEN CITY, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing...
► Artikel lesen
BEYOND AIR Aktie jetzt für 0€ handeln
04.03.Beyond Air Inc (XAIR) Expands Focus on Nitric Oxide Therapies1
20.02.Beyond Air comments on review of high-dose nitric oxide therapy1
20.02.Beyond Air Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections3
13.02.Insights into Beyond Air Q3 Earnings1
13.02.Beyond Air GAAP EPS of -$0.85 misses by $0.03, revenue of $2.2M beats by $0.05M2
13.02.Beyond Air Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update436Increased revenue by 105% year-over-year (YoY) to $2.2 million in fiscal Q3 Maintain fiscal year 2026 revenue guidance of $8-10 million $22.3 million pro forma cash, cash equivalents, restricted...
► Artikel lesen
12.02.Beyond Air Q3 2026 Earnings Preview1
12.02.Beyond Air Earnings Preview1
02.02.Beyond Air, Inc. - 8-K, Current Report4
20.01.Beyond Air, Inc. - 8-K, Current Report1
14.01.Beyond Air secures $5 million in private placement financing4
13.01.Beyond Air, Inc. Shares Surge 166% On NeuroNOS Transaction4
13.01.XTL Biopharmaceuticals übernimmt Autismus-Spezialisten NeuroNOS von Beyond Air19
13.01.XTL acquires autism therapeutics firm NeuroNOS from Beyond Air3
13.01.XTL Biopharmaceuticals Acquires 85% of Beyond Air's Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership2
30.12.25Beyond Air, Inc. - 8-K, Current Report-
30.12.25Beyond Air Names Dan Moorhead CFO1
Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1